



## **Shanghai Genomics Ltd. and Immuno-Biological Laboratories Co., Ltd. Signed Licensing Agreement to Explore Chinese Market**

**TOKYO, June 21, 2010** – A clinical-stage biopharmaceutical company, GNI Ltd. (GNI) which focusing on Chinese healthcare market and a Japanese leading company of research and development of antibodies, disease animal models and various clinical reagents, Immuno-Biological Laboratories Co., Ltd. (IBL) has announced today that GNI's wholly owned subsidiary, Shanghai Genomics Inc., (SG) has signed an agreement to license certain antibody technology from IBL to develop, produce, and sell such reagents fast-expanding cancer diagnostic market in China.

In the past several years, both GNI and SG have achieved in research and development service section of pharmaceutical industry. Not only the research and development service section constitutes an important part of internal drug development but also collaborates with Chinese and international pharmaceutical companies on many different projects. Genomics research tools generate various antibodies that have been sold worldwide including Japan and China. GNI believes that such services bring significant revenue stream and international recognition for the company prior GNI achieves obtaining its first grade drug approval in China.

IBL has been acting important roles for exploring causes of serious diseases such as cancers and inflammatory related diseases and has been continually researching and developing of high quality antibodies against such diseases in decades. Such antibodies developed by IBL can be utilized for assay kits against various diseases in China. As the industry of R&D of Assay kit in China is not enough developed yet, the industry should significantly grow in the future.

Dr. Ying Luo, President and CEO of GNI and SG and Mr. Tsutomu Seito, President of IBL said, "Collaborating of both parties' advantages (IBL's advanced technology of R&D of antibodies for assays and GNI's strong background of business in Chinese market based in China) bring synergy effect to both parties and that would be a good start as a first step of penetrating into Chinese healthcare market. Upon this first step, we look forward to working more collaboratively in the future."

### **About GNI**

GNI was founded as a genomic analyzing drug development company in 2001 and acquired Shanghai Genomics (founded in 2001) in June 2005. GNI develops, manufactures and sales new drugs and reagents in China and also involves collaborative research with major international pharmaceutical companies in both Japan and China. Its head quarter is located in Tokyo, Japan. Majority of R&D, manufacturing process and sales and marketing activities are based in China. For further information, please visit [www.gnipharma.com](http://www.gnipharma.com) and [www.shanghaiagnostics.com](http://www.shanghaiagnostics.com).

### **About IBL**

IBL was founded as an R&D-based company specialized in the development of antibodies against proteins related to cancers, inflammatory diseases, and brain and nerve system related diseases. Based on the accumulated immunological study and research of antibodies, IBL has developed various businesses such as developing, manufacturing, producing, supplying, customizing of antibodies, assays, animal models, and licensing related to seeds for drug discovery, sales and marketing of water soluble creatine product and so on. By supplying these various services and products around the world, IBL has been continually making significant contribution to the medical industry. Its headquarters is located in Gunma, Japan. Total number of employees is 70. For further information, please visit <http://www.ibl-japan.co.jp>

**For further inquiries**

Shinobu Tanaka      Tel: +81 (03) 5326-3097

Email: [ir@gene-networks.com](mailto:ir@gene-networks.com)

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to," "will," "intend to," "strive to" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. GNI does not undertake any obligation to update forward-looking statements.